Bladder cancer study results accepted for publication in Nature Communications
Hamlet Pharma is proud to announce that the report of the phase I/II bladder cancer trial has been accepted for publication in Nature Communications; a leading international journal.The paper is entitled "Bladder cancer therapy using a conformationally fluid tumoricidal peptide complex" andhas been accepted for publication in Nature Communications. The Nature journals are extremely competitive and only accept innovative science of highest quality and with significant interest for a discerning audience. The journals are widely read, with a high impact. The paper analyses the structure of